Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $87 to $88.